Becton, Dickinson and Company $BDX Shares Sold by Good Steward Wealth Advisors LLC

Good Steward Wealth Advisors LLC decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,769 shares of the medical instruments supplier’s stock after selling 191 shares during the quarter. Good Steward Wealth Advisors LLC’s holdings in Becton, Dickinson and Company were worth $305,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Northcape Wealth Management LLC increased its stake in Becton, Dickinson and Company by 0.5% during the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock worth $2,248,000 after acquiring an additional 51 shares during the last quarter. Alpha Omega Wealth Management LLC boosted its position in shares of Becton, Dickinson and Company by 5.7% during the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier’s stock worth $225,000 after buying an additional 53 shares during the period. Brady Family Wealth LLC boosted its position in shares of Becton, Dickinson and Company by 1.2% during the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock worth $989,000 after buying an additional 53 shares during the period. Diversified Trust Co boosted its position in shares of Becton, Dickinson and Company by 4.7% during the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock worth $272,000 after buying an additional 53 shares during the period. Finally, REAP Financial Group LLC boosted its position in shares of Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 55 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 1.8%

NYSE:BDX opened at $187.23 on Friday. The stock has a 50-day simple moving average of $186.46 and a 200-day simple moving average of $191.49. The stock has a market cap of $53.66 billion, a P/E ratio of 33.67, a P/E/G ratio of 1.42 and a beta of 0.27. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to analysts’ expectations of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is currently 74.82%.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,965 shares of company stock valued at $551,536. Insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Citigroup lowered Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and lowered their price target for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. Morgan Stanley raised their price target on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Wells Fargo & Company lifted their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a report on Friday, August 8th. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Four equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average target price of $211.44.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.